Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Psych MEQs / SAQsPsychopharmacology — mood stabilisers

Psych MEQs / SAQs · Psychopharmacology — mood stabilisers

Mood stabiliser choice, lithium monitoring and pregnancy hierarchy (MEQ)

FRANZCP-style MEQ on mood stabiliser selection, lithium monitoring, valproate pregnancy hierarchy, lamotrigine titration, and lithium toxicity prevention.

20 marks20 min1 min readVerification in progress

Target exams

FRANZCPMRCPsychABPNMD-DNB
On this page
Study tools

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 29-year-old woman with bipolar I disorder is recovering from a second manic episode treated with olanzapine. She wishes to plan pregnancy in 12–18 months, currently uses inconsistent contraception, eGFR 92, TFT normal, BMI 29. She asks whether valproate is 'stronger' than lithium for staying well. (i) Justify your preferred long-term mood stabiliser strategy with trial evidence (BALANCE and related). (ii) Detail lithium baseline tests, target trough concept, and early monitoring if lithium is chosen. (iii) Explain why valproate is not appropriate as her routine maintenance and what counselling is required if any anticonvulsant is discussed. (iv) Outline lamotrigine’s niche and titration caveats. (v) List three drug interactions that raise lithium and how you would manage an intercurrent dehydration illness. (20 marks)

Model answer

Reveal model answerShowHide

(i) Preferred strategy and evidence. For bipolar I maintenance after recurrent mania, lithium is the preferred long-term cornerstone when monitoring is feasible: BALANCE showed lithium monotherapy superior to valproate monotherapy for relapse prevention, with combination also effective; lithium also carries an anti-suicide evidence signal. Shared decision covers benefits, monitoring burden, and future pregnancy planning rather than marketing “strength.” Continue or taper olanzapine based on residual symptoms and metabolic risk once a stabiliser is established.[1][2]

(ii) Lithium practicalities. Baseline: eGFR/creatinine, U&E, TFT, calcium, pregnancy test, weight, ECG if indicated. Educate on hydration and interacting drugs. Levels are 12-hour troughs at steady state after initiation/dose change. ISBD/IGSLI-informed maintenance targets commonly around 0.6–0.8 mmol/L for many adults, individualised. Recheck early, then periodically with renal/thyroid/calcium surveillance.[3][7]

(iii) Valproate hierarchy. Do not recommend valproate as routine maintenance given pregnancy potential. EURAP shows high, dose-dependent major malformation risk; Meador NEAD shows adverse cognitive outcomes after fetal valproate. If any discussion of valproate ever occurs under exceptional frameworks, document highly effective contraception, teratogen counselling, and specialist oversight — her inconsistent contraception is a hard stop for casual use.[4][5]

(iv) Lamotrigine. Best for depression-pole prevention/maintenance rather than rapid antimanic rescue. Slow titration (classic 25 mg then 50 mg fortnightly skeleton toward ~200 mg as tolerated); slower with valproate; stop for concerning rash.[6][8]

(v) Interactions and illness. NSAIDs, ACE inhibitors/ARBs, and thiazides raise lithium. In gastroenteritis/dehydration: hold lithium, rehydrate, urgent level and renal panel when unwell, restart only when eating/drinking and levels safe — prevent chronic accumulation toxicity.[7]

Psychiatry Fellowship Pro

Continue reading

You have read the opening of this meqs / saq. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship library.

Sign in to continueSee pricing
References8ShowHide
  1. [1]Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial Lancet, 2010.PMID 20092882
  2. [2]Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis BMJ, 2013.PMID 23814104
  3. [3]Nolen WA, Licht RW, Young AH, et al. What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium Bipolar Disord, 2019.PMID 31112628
  4. [4]Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry Lancet Neurol, 2011.PMID 21652013
  5. [5]Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs N Engl J Med, 2009.PMID 19369666
  6. [6]Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder J Clin Psychiatry, 2004.PMID 15096085
  7. [7]Gitlin M Lithium side effects and toxicity: prevalence and management strategies Int J Bipolar Disord, 2016.PMID 27900734
  8. [8]Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group J Clin Psychiatry, 1999.PMID 10084633
Psychiatry Fellowship Pro

$29/ monthor $279 / year

The complete Psychiatry Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousMirtazapine vs bupropion phenotype matching and combination literacy (MEQ)Psychopharmacology — atypical and multimodal antidepressantsNextMotivational interviewing in dual diagnosis engagement (MEQ)Professional practice — psychological therapies